Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Rises By 126.7%

20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 291,990 shares, an increase of 126.7% from the May 31st total of 128,775 shares. Currently, 2.8% of the company’s shares are sold short. Based on an average trading volume of 2,692,121 shares, the days-to-cover ratio is presently 0.1 days.

20/20 Biolabs Stock Up 9.9%

Shares of 20/20 Biolabs stock traded up $0.05 during trading hours on Wednesday, hitting $0.60. The company’s stock had a trading volume of 966,785 shares, compared to its average volume of 650,650. 20/20 Biolabs has a twelve month low of $0.51 and a twelve month high of $50.00. The company’s fifty day simple moving average is $1.09.

Get 20/20 Biolabs alerts:

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million during the quarter.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AIDX. Weiss Ratings started coverage on shares of 20/20 Biolabs in a research report on Thursday, May 14th. They set a “sell (e-)” rating for the company. Wall Street Zen raised shares of 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. Finally, Maxim Group initiated coverage on shares of 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

Check Out Our Latest Analysis on AIDX

About 20/20 Biolabs

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.

Featured Articles

• Five stocks we like better than 20/20 Biolabs
• Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
• Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push
• 3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test
• 3 ETFs Offering Exposure to Latin America’s Stock Market Rally

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.